Bortezomib-based therapy for newly diagnosed multiple myeloma
patients ineligible for autologous stem cell transplantation:
Czech Registry Data

J 2021

Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data

SANDECKÁ, Viera; Luděk POUR; Ivan SPICKA; Jiri MINARIK; Jakub RADOCHA et al.

Základní údaje

Originální název

Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data

Autoři

Vydání

European Journal of Haematology, Hoboken, Wiley-Blackwell, 2021, 0902-4441

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.674

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/21:00123612

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

bortezomib; multiple myeloma; patient; treatment

Štítky

14110518, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 1. 2022 13:46, Mgr. Tereza Miškechová

Anotace

V originále

Objectives This study compared the use of bortezomib in different combination regimens in newly diagnosed multiple myeloma (NDMM) patients who were transplant ineligible. Patients and Methods We analyzed data from the Registry of Monoclonal Gammopathies (RMG) of the Czech Myeloma Group (CMG) to provide real-world evidence of outcome for 794 newly diagnosed MM transplant ineligible patients. The most frequently used regimen was VCd (bortezomib-cyclophosphamide-dexamethasone) (47.5%) over VMP (bortezomib-melphalan-prednisone) (21.7%), BDd (bortezomib-doxorubicin-dexamethasone) (9.8%), and VTd (bortezomib-thalidomide-dexamethasone) (2.9%). Results The overall response rate (ORR) was 69.2% (478/691), including 12.6% (>= CR); 34.7% very good partial responses (VGPR); and 21.9% partial responses (PR). Among triplet regimens, VMP was the most effective regimen compared to VCd, BDd, and VTd. Median PFS was 22.3 vs. 18.5 vs. 13.7 vs. 13.8 mo, (P = .275), respectively, and median OS was 49 vs. 41.7 vs. 37.9 vs. 32.2 mo (P = .004), respectively. The most common grade 3-4 toxicities were anemia in 17.4% and infections in 18% of patients. Conclusion Our study confirmed that bortezomib-based treatment is effective and safe in NDMM transplant ineligible patients, especially VMP, which was identified as superior between bortezomib-based induction regimens not only in clinical trials, but also in real clinical practice.

Citovat

SANDECKÁ, Viera; Luděk POUR; Ivan SPICKA; Jiri MINARIK; Jakub RADOCHA; Tomas JELINEK; Adriana HEINDORFER; Petr PAVLICEK; Michal SYKORA; Alexandra JUNGOVA; Petr KESSLER; Marek WROBEL; David STAROSTKA; Jana ULLRYCHOVA; Lukas STEJSKAL; Martin ŠTORK; Jan STRAUB; Tomas PIKA; Lucie KUBÍNOVÁ; Sabina ŠEVČÍKOVÁ; Vladimir MAISNAR a Roman HAJEK. Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. European Journal of Haematology. Hoboken: Wiley-Blackwell, 2021, roč. 107, č. 4, s. 466-474. ISSN 0902-4441. Dostupné z: https://doi.org/10.1111/ejh.13683.

@article{1818698,
   author = {Sandecká, Viera and Pour, Luděk and Spicka, Ivan and Minarik, Jiri and Radocha, Jakub and Jelinek, Tomas and Heindorfer, Adriana and Pavlicek, Petr and Sykora, Michal and Jungova, Alexandra and Kessler, Petr and Wrobel, Marek and Starostka, David and Ullrychova, Jana and Stejskal, Lukas and Štork, Martin and Straub, Jan and Pika, Tomas and Kubínová, Lucie and Ševčíková, Sabina and Maisnar, Vladimir and Hajek, Roman},
   article_location = {Hoboken},
   article_number = {4},
   doi = {https://doi.org/10.1111/ejh.13683},
   keywords = {bortezomib; multiple myeloma; patient; treatment},
   language = {eng},
   issn = {0902-4441},
   journal = {European Journal of Haematology},
   title = {Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data},
   url = {https://onlinelibrary.wiley.com/doi/10.1111/ejh.13683},
   volume = {107},
   year = {2021}
}

TY  - JOUR
ID  - 1818698
AU  - Sandecká, Viera - Pour, Luděk - Spicka, Ivan - Minarik, Jiri - Radocha, Jakub - Jelinek, Tomas - Heindorfer, Adriana - Pavlicek, Petr - Sykora, Michal - Jungova, Alexandra - Kessler, Petr - Wrobel, Marek - Starostka, David - Ullrychova, Jana - Stejskal, Lukas - Štork, Martin - Straub, Jan - Pika, Tomas - Kubínová, Lucie - Ševčíková, Sabina - Maisnar, Vladimir - Hajek, Roman
PY  - 2021
TI  - Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data
JF  - European Journal of Haematology
VL  - 107
IS  - 4
SP  - 466-474
EP  - 466-474
PB  - Wiley-Blackwell
SN  - 09024441
KW  - bortezomib
KW  - multiple myeloma
KW  - patient
KW  - treatment
UR  - https://onlinelibrary.wiley.com/doi/10.1111/ejh.13683
N2  - Objectives This study compared the use of bortezomib in different combination regimens in newly diagnosed multiple myeloma (NDMM) patients who were transplant ineligible. Patients and Methods We analyzed data from the Registry of Monoclonal Gammopathies (RMG) of the Czech Myeloma Group (CMG) to provide real-world evidence of outcome for 794 newly diagnosed MM transplant ineligible patients. The most frequently used regimen was VCd (bortezomib-cyclophosphamide-dexamethasone) (47.5%) over VMP (bortezomib-melphalan-prednisone) (21.7%), BDd (bortezomib-doxorubicin-dexamethasone) (9.8%), and VTd (bortezomib-thalidomide-dexamethasone) (2.9%). Results The overall response rate (ORR) was 69.2% (478/691), including 12.6% (>= CR); 34.7% very good partial responses (VGPR); and 21.9% partial responses (PR). Among triplet regimens, VMP was the most effective regimen compared to VCd, BDd, and VTd. Median PFS was 22.3 vs. 18.5 vs. 13.7 vs. 13.8 mo, (P = .275), respectively, and median OS was 49 vs. 41.7 vs. 37.9 vs. 32.2 mo (P = .004), respectively. The most common grade 3-4 toxicities were anemia in 17.4% and infections in 18% of patients. Conclusion Our study confirmed that bortezomib-based treatment is effective and safe in NDMM transplant ineligible patients, especially VMP, which was identified as superior between bortezomib-based induction regimens not only in clinical trials, but also in real clinical practice.
ER  -

SANDECKÁ, Viera; Luděk POUR; Ivan SPICKA; Jiri MINARIK; Jakub RADOCHA; Tomas JELINEK; Adriana HEINDORFER; Petr PAVLICEK; Michal SYKORA; Alexandra JUNGOVA; Petr KESSLER; Marek WROBEL; David STAROSTKA; Jana ULLRYCHOVA; Lukas STEJSKAL; Martin ŠTORK; Jan STRAUB; Tomas PIKA; Lucie KUBÍNOVÁ; Sabina ŠEVČÍKOVÁ; Vladimir MAISNAR a Roman HAJEK. Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. \textit{European Journal of Haematology}. Hoboken: Wiley-Blackwell, 2021, roč.~107, č.~4, s.~466-474. ISSN~0902-4441. Dostupné z: https://doi.org/10.1111/ejh.13683.

Přehled o publikaci